Streetbeat News

IMNM

Immunome, Inc.

Industry

Biotechnology

Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.

Open

9.06

Mkt cap

743M

Volume

453K

High

9.16

P/E Ratio

-1.10

52-wk high

26.70

Low

8.75

Div yield

N/A

52-wk low

8.38

Immunome, Inc. has dosed the first patient in its Phase 1 trial of IM-1021, a ROR1-targeted ADC, marking a significant step in its cancer therapy development.

Portfolio Pulse from

March 10, 2025 | 12:00 pm

Immunome, Inc. announced inducement grants of stock options to new employees under Nasdaq Listing Rule 5635(c)(4).

Portfolio Pulse from

March 06, 2025 | 9:15 pm

Immunome, Inc. has successfully closed an upsized public offering, raising significant capital through the sale of 22,258,064 shares, including additional shares purchased by underwriters. The offering was priced at $7.75 per share.

Portfolio Pulse from

January 31, 2025 | 9:15 pm

Immunome is poised to challenge its competitors with its new product, Varegacestat. This development could enhance its market position and attract investor interest.

Portfolio Pulse from

January 30, 2025 | 3:45 pm

Immunome, Inc. has announced the pricing of an upsized public offering of 19,354,839 shares of its common stock at $7.75 per share, aiming to raise significant capital for its cancer therapy developments.

Portfolio Pulse from

January 30, 2025 | 4:30 am

Immunome, Inc. announced inducement grants of stock options to new employees under Nasdaq Listing Rule 5635(c)(4).

Portfolio Pulse from

January 02, 2025 | 11:30 pm

Immunome, Inc. announced inducement grants of non-statutory stock options to 15 new employees under its 2024 Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4).

Portfolio Pulse from

December 02, 2024 | 11:45 pm

Immunome, Inc. (IMNM) reported a Q3 loss of $0.78 per share, missing the Zacks Consensus Estimate of a $0.60 loss. This is a larger loss compared to $0.36 per share a year ago.

Portfolio Pulse from

November 13, 2024 | 11:30 pm

Immunome, Inc. (NASDAQ:IMNM) presented promising preclinical data for its cancer therapy IM-1021 and proprietary ADC payload HC74, showing superior potency and efficacy in preclinical models. An IND submission is expected in Q1 2025.

Portfolio Pulse from Benzinga Newsdesk

October 29, 2024 | 12:11 pm

Wedbush analyst David Nierengarten has reiterated an Outperform rating for Immunome (NASDAQ:IMNM) and maintained a price target of $33.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2024 | 3:06 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.